Amplifica’s human trial medicine for hair growth shows 15% more efficacy
Amplifica Holdings Group Inc.’s first-in-human trial of an injectable medicine for treating hair loss has shown a more than 15% increase in non-vellus.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Amplifica Holdings Group Inc.’s first-in-human trial of an injectable medicine for treating hair loss has shown a more than 15% increase in non-vellus.
HQ Team September 27, 2024: The Central Drugs Standard Control Organisation (CDSCO) of India recently issued a notification regarding identifying 52 spurious drugs.
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.
HQ Team December 4, 2023: Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood.